Table 1 Summary of all tumors developed in the animals during the course of the study

3209

male

18 mon

Prkar2a +/−

DLBCL and HS rich

3150

female

18 mon

Prkar2a +/−

DLBCL

3345

male

20 mon

Prkar2a +/−

MZL

3485

male

22 mon

Prkar2a +/−

HS

2378

male

18 mon

Prkar2a +/−

HS

Lung adenoma

2379

male

18 mon

Prkar2a +/−

HS

2552

female

25 mon

Prkar2a +/−

HS

3078

female

23 mon

Prkar2a +/−

HS

3305

female

24 mon

Prkar2a +/−

Liver, Lung, Pancreas: lymphoid infiltrates

Liver: lymphoplasmatic infiltrates

3210

male

24 mon

Prkar2a +/−

HS

3211

male

24 mon

Prkar2a +/−

Liver hemangiosarcoma

3217

male

16 mon

Prkar2a +/−

DLBCL and HS

2622

male

17 mon

Prkar2a +/−

HS

MS1200161

male

16 mon

Prkar2a +/−

HS

3306

female

19 mon

Prkar2a +/−

HS

2494

female

18 mon

Prkar2a +/−

HS

3794

male

6 mon

Prkar2a +/−

Spleen Lymphoid Hyperplasia

2545

male

20 mon

Prkar2a +/−

Plasmacytoma

3753

female

6 mon

Prkar2a +/−

Spleen Lymphoid Hyperplasia

4071

female

18 mon

Prkar2a −/−

HS

4072

female

18 mon

Prkar2a −/−

HS

2537

female

18 mon

Prkar2a −/−

DLBCL and HS rich

3988

female

15 mon

Prkar1a +/−; Prkar2a +/−

Liver - Early adenoma

2383

female

24 mon

WT

HS

3146

female

18 mon

WT

EMZ

3852

male

17 mon

WT

MZL

3437

male

18 mon

Prkar2b +/−

Lymph nodes: plasma cell tumor

3436

female

18 mon

Prkar2b +/−

Lung: adenoma

Spleen plasma cells

3147

female

18 mon

Prkar2b +/−

EMZ

2860

female

25 mon

Prkar2b +/−

HS

1941

female

16 mon

Prkar2b +/−

DLBCL

2204

female

24 mon

Prkar2b +/−

HS

2939

female

24 mon

Prkar1a +/−

MZL

Lymph nodes plasmacytosis

3069

male

24 mon

Prkar1a +/−

Lung: fibrosarcoma; adenoma

3087

male

22 mon

Prkar1a +/−

HS

1354

male

23 mon

Prkar1a +/−

Early HS

Trachea lymphoplasmacytic